Sovremennye strategii antianginal'noy farmakoterapii khronicheskoy ishemicheskoy bolezni serdtsa
- Authors: Ashikhmin Y.I1
-
Affiliations:
- Issue: No 14 (2012)
- Pages: 54-59
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279843
- ID: 279843
Cite item
Open Access
Access granted
Abstract
Recent advances in molecular biology of atherosclerosis revealed a new understanding of the pathophysiology of coronary heart disease, which allowed the development of new methods of treatment aimed to relieving patient’s suffering and to modify the course of illness. This overview presents the tactics of antianginal therapy in patients with chronic coronary heart disease in terms of interest of practitioners.
Full Text
References
- Ambrose JA, Srikanth S. Vulnerable plaques and patients: improving prediction of future coronary events. Am J Med 2010;123(1):10-6.
- Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1998;56(1):9-13.
- Sharif F, Lohan D, Wijns W. Non-invasive detection of vulnerable coronary plaque. World J Cardiol 2011;3(7):219-29.
- Sharma R, Sharma R, Voelker D, et al. Cardiac risk stratification: Role of the coronary calcium score. Vasc Health Risk Manag 2010;6:603-11.
- Ramkumar PG, Mitsouras D, Feldman CL, et al. New advances in cardiac computed tomography. Curr Opin Cardiol 2009;24(6): 596-603.
- Ko YG, Le VC, Kim BH, Shin DH, et al. Correlations between coronary plaque tissue composition assessed by virtual histology and blood levels of biomarkers for coronary artery disease. Yonsei Med J 2012;53(3):508-16.
- Khan G. Cardiac Drug Therapy, 7th ed, Humana Press, 2007.
- Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9641):807-16.
- Bonow R, Mann D, Zipes D, Libby P, et al. Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine, 9th ed 2011;Saunders.
- Диагностика и лечение стабильной стенокардии. Российские рекомендации (2-й пересмотр). Разработаны Комитетом экспертов ВНОК. М., 2009.
- Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined anti-anginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis 2002;13(8):427-36.
- Jolicoeur E, Henry T, Barsness G. Patients With Coronary Artery Disease Unsuitable for Revascularization: Definition, General Principles, and a Classification. Canadian Journal of Cardiology 2012;28:50-9.
- Малышева А.М., Марцевич С.Ю., ГинзбургМ.Л. Применение никорандила - препарата с дополнительными кардиопротективными свойствами у пациентов с ишемической болезнью сердца // Терапевтический архив 2011. Т. 83. № 9.; С 14-9.
- Лупанов В.П. Ранолазин при ишемической болезни сердца // Рациональная фармакотерапия в кардиологии 2012. № 8(1). лишь пациентами, которым не может быть проведена реваскуляризация миокарда.
- Fox K, Garcia M, Ardissino D, et al. Management of Stable Angina Pectoris ESC Clinical Practice Guidelines EHJ 2006;27: 1341-81.
- Palaniswamy C, Aronow W. Treatment of Stable Angina Pectoris. American Journal of Therapeutics 2011;18:138-52.
- Briones E, Lacalle JR, Marin I. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev 2009;CD003712.
- Tinkel J, Hassanain H, Khouri S. Cardiovascular Antioxidant Therapy: A Review of Supplements, Pharmacotherapies, and Mechanisms. Cardiology in Review 2012;20:77-83.
- Дайджест новостей. Редакторская колонка // Медицинские технологии 2012. № 1(7). С. 8.
- European Medicines Agency recommends restricting use of trimetazidine-containing medicines. Restricted indication for patients with stable angina pectoris and deletion of existing indications for treatment of vertigo, tinnitus and vision disturbance. EMA/ CHMP/4 1 7861,2012;(http://www. emea.europa.eu/docs/en/GB/dBcument_ library/Press_release/2012/06/WC5001 29070.pdf).
Supplementary files
